Clinical presentation of abdominal tuberculosis in HIV seronegative adults

BMC Gastroenterology

Table 4 The results of the diagnostic laboratory methods, the rate of abnormality in imaging and invasive methods, and definitive diagnosis in divided groups based upon the clinical presentation.

Groups*	I (n = 24)	II (n = 24)	III (n = 22)	IV (n = 9)	V (n = 9)	P
WBC (/mm3 × 1000)	10 ± 4	8.7 ± 2.6	7.7 ± 1.8	14 ± 3.7	7.3 ± 2.8	0.002
ESR(mm/h)	67 ± 21	65 ± 31	71 ± 20	69 ± 21	72 ± 26	0.842
Tuberculin skin test (mm)	17 ± 7	18 ± 6.5	13 ± 7	18 ± 11	16 ± 9	0.119
AFB in sputum %	12.5	4.5	18.2	25	11	0.602
Chest X-ray %	54.2	27.5	40.9	66.6	22.2	0.448
APG %	20.8	12.5	31.8	66.7	0	0.014
Abdominal CT %	91.7	100	90.9	100	77.8	0.196
** Colonoscopy %	62.5 (5/8)	7.5 (2/15)	90.9 (20/22)	75 (3/4)	33.3 (1/3)	0.04
Operation %	54.2	54.2	33.3	75	22.2	0.156
Diagnosis %
Evidence based	79.2	83.3	86.4	88.9	88.9
Histopathologic	62.5	50	45.5	44.4	55.6
Microbiologic	4.2	12.5	9.1	33.3	11.1	0.933
H+M	12.5	20.8	31.8	11.1	22.2
ETT%	20.8	16.7	13.6	11.1	11.1

*Group I, non-specific abdominal pain; Group II, ascites; Group III, alteration in bowel habit (diarrhea or constipation or together); Group IV, acute abdomen; Group V, others (jaundice, dysphagia, fistula, fever of unknown origin, mass, weight loss);
** The percent in patients with colonoscopy performed WBC, white blood cell count; ESR, erythrocyte sedimentation rate; AFB, acid-fast bacteria; APG, abdominal plain graphy; CT, computed tomography; H, histopathologic; M, microbiologic; ETT, empiric therapeutic trial. P value of less than 0.05 was considered to indicate the statistical significance in between groups.

ISSN: 1471-230X